The Metabolic,Vascular and Inflammatory effects of Conjugated Linoleic acid in patients with the Metabolic Syndrome. - NA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003197-17-GB

Enrollment

Registered

2006-07-22

Start date

2006-09-13

Completion date

Unknown

Last updated

2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METABOLIC SYNDROME

Interventions

Product Name: Clarinol G-80 Product Code: NA Pharmaceutical Form: Capsule* Product Name: C9,t11 CLA-TG capsules Product Code: NA Pharmaceutical Form: Capsule*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with the Metabolic syndrome as defined by the NCEP ATP 3 criteria with atleast 3 of the following 1.Fasting plasma glucose > 5.6mmol/l 2.Serum Triglycerides > 1.7mmol/l 3.Serum HDL Cholesterol 130/85 5.Abdominal obesity Waist girth >102cms in males > 88 cms in females Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1.Patients with Diabetes 2.Patients on NSAIDs,Aspirin 3.pregnancy and Lactation 4.Acute Renal and liver disease 5.Acute illness.

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine the effects of Conjugated linoleic acid on inflammation through RAGE expression in males and females with the metabolic syndrome.;Secondary Objective: To establish the effects of Conjugated linoleic acid on insulin sensitivity,Body mass index,Artery stiffness,endothelial and platelet function.;Primary end point(s): The effect of Conjugated linoleic acid on inflammation and RAGE expression.	—

Measure

Time frame

Main Objective: To determine the effects of Conjugated linoleic acid on inflammation through RAGE expression in males and females with the metabolic syndrome.;Secondary Objective: To establish the effects of Conjugated linoleic acid on insulin sensitivity,Body mass index,Artery stiffness,endothelial and platelet function.;Primary end point(s): The effect of Conjugated linoleic acid on inflammation and RAGE expression.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026